BPTH Bio-Path Holdings
- 2.240
- 0.0000.00%
Bio-Path Holdings News
Bio-Path Holdings Inc (BPTH) Q1 2024 Earnings Call Transcript Highlights: Strategic Advances ...
Q1 2024 Bio Path Holdings Inc Earnings Call
Earnings Call Summary | Bio-Path Holdings(BPTH.US) Q1 2024 Earnings Conference
The following is a summary of the Bio-Path Holdings Inc. (BPTH) Q1 2024 Earnings Call Transcript:Financial Performance:Bio-Path Holdings reported a net loss of $3.2 million or $4.88 per share for Q1 2
Bio-Path Holdings Inc. (BPTH) Q1 2024 Earnings Call Transcript
Bio-Path Holdings Inc. (BPTH) Q1 2024 Earnings Call Transcript
Bio-Path Holdings 1Q Loss/Shr $4.88 >BPTH
Bio-Path Holdings 1Q Loss/Shr $4.88 >BPTH
Press Release: Bio-Path Holdings Reports First Quarter 2024 Financial Results
Bio-Path Holdings Reports First Quarter 2024 Financial Results Marks Progress Across Key Clinical and Corporate Goals Strengthened Balance Sheet with $3.5 Million Conference Call to be Held Today a
Bio-Path Holdings Q1 2024 GAAP EPS $(4.88) Misses $(4.54) Estimate
Bio-Path Holdings Q1 2024 GAAP EPS $(4.88) Misses $(4.54) Estimate
Bio-Path Holdings | 10-Q: Quarterly report
Bio-Path Holdings to Announce First Quarter 2024 Financial Results on May 15, 2024
HOUSTON, May 08, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (NASDAQ: BPTH) a biotechnology company leveraging its proprietary DNAbilize antisense RNAi nanoparticle technology to develop a po
Bio-Path Holdings Has Been Granted Israeli Patent Number 269608 Titled "COMPOSITIONS COMPRISING P-ETHOXY NUCLEIC ACIDS FOR STAT3 INHIBITION FOR USE IN TREATING CANCER OR AUTOIMMUNE DISEASE"
Bio-Path Holdings Has Been Granted Israeli Patent Number 269608 Titled "COMPOSITIONS COMPRISING P-ETHOXY NUCLEIC ACIDS FOR STAT3 INHIBITION FOR USE IN TREATING CANCER OR AUTOIMMUNE DISEASE"
Bio-Path Holdings, Sunshine Biopharma, INVO Bioscience Among Healthcare Movers
Why Vaxxinity Shares Are Trading Lower By Around 55%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Vaxxinity, Inc. (NASDAQ:VAXX) fell sharply during Monday's session after the company announced its intention to voluntarily delist and deregister its Class A common stock.
MRIN, WISA and SMFL Among Mid-day Movers
Lexicon Pharmaceuticals, Bio-Path Holdings, Protara Therapeutics Among Healthcare Movers
Bio-Path Closes $1.2 Million Share Offering
Bio-Path Holdings (BPTH) said Friday that it has closed its registered direct offering, selling 375,000 shares at $3.225 per share for gross proceeds of about $1.2 million. The company said it also co
Press Release: Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
Bio-Path Holdings, Inc. Announces Closing of $1.2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules HOUSTON, April 19, 2024 (GLOBE NEWSWIRE) -- Bio-Path Holdings, Inc., (Nasd
Why Wang & Lee Group Shares Are Trading Higher By 38%; Here Are 20 Stocks Moving Premarket
Shares of Wang & Lee Group, Inc. (NASDAQ:WLGS) rose sharply in today's pre-market trading after the company reported a year-over-year increase in FY23 financial results.Wang & Lee Group posted a FY23
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersBio-Path Hldgs (NASDAQ:BPTH) stock moved upwards by 9.0% to $4.58 during Thursday's after-market session. The company's market cap stands at $3.4 million. Biora Therapeutics (NASDAQ:BIOR) share
Bio-Path Shares Pare Gains on Registered Direct Offering News
By Josh Beckerman Bio-Path Holdings shares pared their gains after the biotechnology company announced a $1.2 million registered direct offering. The stock more than doubled after a favorable Thursd
Roth MKM: Reiterates Bio-Path Hldgs (BPTH.US) rating, adjusted from buy to buy rating, target price of $40.00.
Roth MKM: Reiterates Bio-Path Hldgs (BPTH.US) rating, adjusted from buy to buy rating, target price of $40.00.
Analysis
Price Target
No Data
